What benefits does Ambulanzpartner offer for research?

In addition to improving care processes, digitalization on the portal offers new opportunities for medical research. Systematic analysis of treatment data (in particular medication, nutritional products and ventilation therapy) allows existing therapies to be optimized and new treatment strategies to be developed. Of particular importance is the linking of treatment data with data from the ALS and SMA functional scale (ALFRS-R and FRS) and the progression marker neurofilament light chain (NfL), which are also recorded on the ambulatory partner platform. In this way, it can be analyzed whether and how certain medications or therapeutic procedures can slow down ALS or SMA and improve the prognosis. It is also possible to determine which aids (especially modern assistance technology) are particularly suitable in certain situations and can compensate for ALS- or SMA-related deficits.